Partial deletion of chromosome 9 syndrome

Partial deletion of chromosome 9 syndrome (also referred to as partial monosomy 9 or 9p deletion syndrome when involving the short arm, or 9q deletion syndrome when involving the long arm) encompasses a group of rare chromosomal disorders caused by the loss of a segment of chromosome 9. The clinical presentation varies considerably depending on the size and specific location of the deleted segment. When the deletion involves the short arm (9p), commonly known as 9p deletion syndrome or Alfi syndrome, affected individuals typically present with intellectual disability, trigonocephaly (a triangular-shaped forehead due to premature fusion of the metopic suture), midface hypoplasia, upslanting palpebral fissures, a flat nasal bridge, long philtrum, and short neck. Congenital heart defects, genital anomalies (particularly in males, including cryptorchidism and ambiguous genitalia related to disorders of sex development), and hypotonia may also be observed. Deletions involving the long arm (9q) can produce a distinct but overlapping set of features including growth retardation, craniofacial dysmorphism, cardiac malformations, and variable degrees of developmental delay. The condition is typically identified at birth or during early infancy based on characteristic physical features and is confirmed through chromosomal analysis such as karyotyping, FISH, or chromosomal microarray. Most cases arise de novo (as new mutations), though some may result from parental balanced chromosomal rearrangements such as translocations. There is no cure for partial deletion of chromosome 9 syndrome. Management is supportive and multidisciplinary, addressing specific symptoms as they arise. This may include surgical correction of craniosynostosis or congenital heart defects, early intervention programs for developmental delays, speech and occupational therapy, and ongoing monitoring by specialists in cardiology, endocrinology, and neurology. Genetic counseling is recommended for affected families to assess recurrence risk.

Common questions about Partial deletion of chromosome 9 syndrome